Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

Genzyme

Status and phase: Terminated; Phase 1

Conditions: Niemann-Pick Disease; Acid Sphingomyelinase Deficiency

Treatments: Drug: rhASM

Study type: Interventional

Funder types: Industry

Identifiers

NCT00410566

SPHINGO00605

Details and patient eligibility

About

The purpose of this study is to determine the safe range of single doses of rhASM administered to adults with ASM deficiency.

Full description

ASM deficiency (ASMD), also known as Niemann-Pick A and B disease, is a rare genetic disorder in which reduced activity of the lysosomal enzyme, ASM, leads to the accumulation of sphingomyelin primarily in macrophages throughout the body. This deficiency results in characteristic features such as hepatosplenomegaly, thrombocytopenia, interstitial lung disease, growth retardation, coronary artery disease, fatigue, and in severe cases, neurodegeneration with death in early childhood. There is no specific treatment for this disease. This Phase 1 safety study will seek to enroll a minimum of 12 and a maximum of 30 eligible adults patients with ASMD with each patient participating for approximately 7 weeks.

Enrollment: 11 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed, informed consent by the patient or legal guardian prior to performing any study-related procedures;
• Have ≤ 0.2 nmol/hr/mg protein ASM activity in peripheral leukocytes, as measured by the reference laboratory;
• Have a diffusing capacity (DLco) > 30% of the predicted normal value;
• Have a spleen volume ≥ 2x normal
• Female patients of childbearing potential must have a serum pregnancy test negative for β-hCG and agree to use a reliable birth control method for the duration of the study.

Exclusion criteria

• Is pregnant or lactating;
• Has received an investigational drug within 30 days prior to study enrollment;
• Has a medical condition, including serious intercurrent illness, active hepatitis B or C or human immunodeficiency virus (HIV) infection, cirrhosis, > stage 3 liver fibrosis, INR >1.5, platelet count < 60.0x10^3/µL, significant cardiac disease (e.g. pulmonary artery pressure > 40 mm Hg, moderate or severe valvular dysfunction, or < 40% left ventricular ejection fraction by echocardiography (ECHO)), or any other extenuating circumstances that may significantly interfere with study compliance including all prescribed evaluations and follow-up activities;
• Has had a major organ transplant (e.g. bone marrow or liver);
• Has had a total splenectomy;
• Has an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >250 IU/L or a total bilirubin >3.6 mg/dL;
• Is unwilling or unable to avoid the use of alcohol, medications that may decrease rhASM activity, medications or herbal supplements that may cause or prolong bleeding, and the use of medications or herbal supplements with potential hepatoxicity within 14 days prior to and 28 days afte the rhASM infusion.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

11 participants in 5 patient groups

1

Experimental group

Treatment:

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

2

Experimental group

Treatment:

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

3

Experimental group

Treatment:

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

4

Experimental group

Treatment:

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

5

Experimental group

Treatment:

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM

Drug: rhASM